Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Peijia Medical's Debt-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Peijia Medical's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Peijia Medical Debt-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Peijia Medical's Debt-to-Asset distribution charts can be found below:
* The bar in red indicates where Peijia Medical's Debt-to-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Peijia Medical (PEJMF) has a Debt-to-Asset of 0.22 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Peijia Medical and its competitors.
Is Peijia Medical's Debt-to-Asset too high?
Peijia Medical's current Debt-to-Asset is 0.22. Overall, Peijia Medical has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Peijia Medical's Debt-to-Asset compare to ABT and SYK?
Peijia Medical's Debt-to-Asset of 0.22 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Medical Devices & Instruments company?
A good Debt-to-Asset depends on the Medical Devices & Instruments industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Peijia Medical and its competitors. Peijia Medical's current Debt-to-Asset is 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Peijia Medical stock overvalued right now?
Peijia Medical (PEJMF) has a current Debt-to-Asset of 0.22. The stock's GF Value™ is $2.54, compared to a current price of $1.39 — trading 45.4% below its estimated fair value. The current Debt-to-Asset is 0.22. Peijia Medical's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Peijia Medical (PEJMF), the current Debt-to-Asset is 0.22 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Peijia Medical (PEJMF) Overvalued in 2026?
Based on GuruFocus' analysis, Peijia Medical stock appears to be undervalued.
The current stock price of $1.39 is trading 45.4% below its estimated GF Value™ of $2.54.
Key valuation signals for PEJMF:
Debt-to-Asset: 0.22
GF Value™: $2.54 vs. price of $1.39 (45.4% below fair value)
No single metric tells the full story. See the PEJMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Peijia Medical Ltd is a Chinese medical device company focused on interventional procedures. It develops and commercializes products for transcatheter valve therapy, used to treat structural heart disease without open surgery, and neurointerventional devices for treating hemorrhagic and ischemic stroke and other cerebrovascular conditions. Its portfolio includes transcatheter aortic valve replacement systems and a range of neurovascular products such as stent retrievers, embolization coils, and balloon catheters. The company sells primarily to hospitals and interventional physicians in China, supported by clinical training and distribution partnerships, and is expanding internationally. Revenue is generated mainly through the sale of approved devices, with a growing contribution from its neurointerventional line, while transcatheter valve products represent a key long-term growth driver. Peijia invests heavily in research and development and clinical trials to advance its pipeline.
80GF Score
Get the complete analysis for PEJMF
Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PEJMF has been successfully added to your 
